MAPT and neurodegenerative disease: Furthermore, 306C7B3 binding was specific to α-synuclein deposits with no immunoreactivity observed to other amyloid deposits characteristic of neurodegenerative diseases such as TDP-43 inclusions in FTLD-TDP and ALS, FUS inclusions in FTLD-FET, tau pathology in PSP and AD, as well as Abeta in AD (Fig. 5).